View Discovery

Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)

FNDR-20081
Foundation for Neglected Disease Research
Sanfetrinem
GlaxoSmithKline, Bill & Melinda Gates Foundation
OTB-658
Institute of Materia Medica, CAMS & PUMC
FNDR 20364
National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India
TB47
Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
GSK839
GlaxoSmithKline
MBX-4888A
Microbiotix, Inc.

Phase 1

TBAJ-587, Diarylquinoline
TB Alliance, University of Auckland, Merck & Co., Inc.
GSK-286
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286
TBI-223
TB Alliance, Institute of Materia Medica
Macozinone (MCZ, PBTZ-169)
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
TBA-7371
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
BVL-GSK098
BioVersys AG, GlaxoSmithKline
Phase 1 Safety, Tolerability and Pharmacokinetics of BVL-GSK098
TBAJ-876 Diarylquinoline
TB Alliance, University of Auckland
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
TBI-166
Institute of Materia Medica, CAMS & PUMC

Phase 2

SPR720
Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
BTZ-043
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
BTZ-043 Multiple Ascending Dose / EBA
Telacebec (Q203)
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Q203 Phase 1b Q203-TB-PI-US002
Phase 2 Telacebec (Q203) EBA
Rifampicin
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
ReDEFINe High-Dose RIF for Meningitis
High-Dose Rifampin
Macozinone (MCZ, PBTZ-169)
Nearmedic Plus LLC
OPC-167832
Otsuka Pharmaceutical Development & Commercialization, Inc.
OPC-167832 Phase 1 / 2 EBA
Sutezolid
Sequella, Inc, TB Alliance
Linezolid
TB Alliance
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube
TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis
GSK 3036656
GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS
EBA, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
Bedaquiline, Pretomanid, Moxifloxacin, Pyrazidamide (BPaMZ)
TB Alliance
SimpliciTB
SQ109
Sequella, Inc
Delpazolid (LCB01-0371)
LegoChem Biosciences, Inc.
NCT02836483 A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.
PredictTB
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP
Levofloxacin
CDC TBTC, NIAID, NIH, DHHS, Boston University
TBTC Study 32, Opti-Q
INH, RIF, PZA, MOX
NexGen EBA
Bedaquiline - Delamanid with MBT for MDR
ACTG 5343 Bedaquiline - Delamanid with MBT for MDR